CareDx's stock experienced a significant decline of 8.58% in post-market trading on Wednesday, as investor sentiment turned negative following major corporate announcements.

Despite reporting robust first-quarter 2026 financial results that included a 39% year-over-year revenue increase to $118 million and adjusted earnings per share of $0.34, both beating analyst estimates, the market focused on the company's concurrent announcement of its agreement to acquire Naveris. The precision oncology diagnostics company will be purchased for $160 million in upfront cash with potential milestone payments of up to $100 million.

Market participants appear to be weighing the substantial costs and integration risks associated with the acquisition against the strong quarterly fundamentals, leading to the sharp sell-off in the extended session.